Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study

References

• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 national survey on drug use and health (HHS Publication No. PEP19-5068, NSDUH series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2019. Retrieved from: https://www.samhsa.gov/data/
   Google Scholar
• Nordstrom BR, Levin FR. Treatment of cannabis use disorders: A review of the literature. Am J Addict. 2007;16:331–42. doi:10.1080/10550490701525665.
   PubMed Web of Science ®Google Scholar
• Sherman BJ, Mcrae-Clark A. Treatment of cannabis use disorder: current science and future outlook. Pharmacotherapy. 2016;36:511–35. doi:10.1002/phar.1747.
   PubMed Web of Science ®Google Scholar
• Babor TF. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol. 2004;72:455–66. doi:http://doi.10.1037/0022-006x.72.3.455.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol. 2000;68:1051–61. doi:http://doi.10.1037/0022-006x.68.6.1051.
   PubMed Web of Science ®Google Scholar
• Carroll KM, Nich C, Lapaglia DM, Peters EN, Easton CJ, Petry NM. Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less. Addiction. 2012;107:1650–59. doi:10.1111/j.1360-0443.2012.03877.x.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. 2006;74:307–16. doi:http://doi.10.1036/0022-006X.4.2.307.
   PubMed Web of Science ®Google Scholar
• Litt MD, Kadden RM, Petry NM. Behavioral treatment for marijuana dependence: randomized trial of contingency management and self-efficacy enhancement. Addict Behav. 2013;38:1764–75. doi:10.1016/j.addbeh.2012.08.011.
   PubMed Web of Science ®Google Scholar
• Moore BA, Budney AJ. Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat. 2003;25:85–89. doi:10.1016/S0740-5472(03)00083-7.
   PubMed Web of Science ®Google Scholar
• Mcrae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009;105:132–38. doi:10.1016/j.drugalcdep.2009.06.022.
   PubMed Web of Science ®Google Scholar
• Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs. 2009;23:543–53. doi:10.2165/00023210-200923070-00001.
   PubMed Web of Science ®Google Scholar
• Chaki S. Beyond ketamine: new approaches to the development of safer antidepressants. Curr Neuropharmacol. 2017;15:963–76. doi:http://doi.10.2174/1570159X15666170221101054.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Levin FR. Individual mindfulness-based psychotherapy for cannabis or cocaine dependence: A pilot feasibility trial. Am J Addict. 2013;22:521–26. doi:10.1111/j.1521-0391.2013.12036.x.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Levin F, Foltin RW, Nunes EV, Hart CL. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine dependent research volunteers. Biol Psychiatry. 2014;76:40–46. doi:http://doi.10.1016/j.biopsych.2013.08.009.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Hart CL, Levin FR, Nunes EV, Foltin RW. Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: A randomized, crossover trial. Mol Psychiatry. 2017;22:76–81. doi:10.1038/mp.2016.39.
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39:13–19. doi:10.1080/02791072.2007.10399860.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23:273–83. doi:10.1016/S0740-5472(02)00275-1.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, Nunes EV. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. Am J Psychiatry. 2019a;177:125–33. doi:http://doi.10.1176/appi.ajp.2019.19070684.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, Choi CJ, Basaraba CN, Pavlicova M, Levin FR. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. Am J Psychiatry. 2019c;176:923–30. doi:10.1176/appi.ajp.2019.18101123.
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar GC. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12:224–31. doi:10.1016/S0924-9338(97)83296-8.
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th. Text Revision. Washington, DC: American Psychiatric Association, 2000.
   Google Scholar
• Carlson EB, Putnam FW. An update on the dissociative experiences scale. Dissociation. 1993; 6: 16–27. http://hdl.handle.net/1794/1539.
   Google Scholar
• Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28:154–62. doi:http://doi.10.1037/a0030992.
   PubMed Web of Science ®Google Scholar
• Bowen S, Chawla N, Collins SE, Witkiewitz K, Hsu S, Grow J, Clifasefi S, Garner M, Douglass A, Larimer ME, et al. Mindfulness-based relapse prevention for substance use disorders: A pilot efficacy trial. Subst Abuse. 2009;30:295–305. doi:10.1080/08897070903250084.
   PubMed Web of Science ®Google Scholar
• Brewer JA, Sinha R, Chen JA, Michalsen RN, Babuscio TA, Nich C, Grier A, Bergquist KL, Reis DL, Potenza MN, et al. Mindfulness training and stress reactivity in substance abuse: results from a randomized, controlled stage I pilot study. Subst Abuse. 2009;30:306–17. doi:10.1080/08897070903250241.
   PubMed Web of Science ®Google Scholar
• Smedslund G, Berg RC, Hammerstrom KT, Steiro A, Leiknes KA, Dahl H, Karlsen K. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 2011;5:CD008063. doi:http://doi.10.1002/14651858.CD008063.pub2.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Mahony A, Choi CJ, Pavlicova M, Brooks D, Mariani JJ, Levin FR. Guanfacine extended-release for cannabis use disorder: A pilot feasibility trial. Am J Drug Alcohol Abuse. 2019b;46:44–48. doi:http://doi.10.1080/00952990.2019.1620259.
   PubMed Web of Science ®Google Scholar
• Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116:142–50. doi:10.1016/j.drugalcdep.2010.12.010.
   PubMed Web of Science ®Google Scholar